Helical Tomotherapy in Local Advanced Breast Cancer Following Mastectomy: Long-term Results and Late Toxicity Analysis

LUIS-PHILIPP RAETHER; MICHAEL SCHEMPP; RUDOLF KLEPPER; HENRIK HAUSWALD; SEBASTIAN HOEFEL; PETER E. HUBER; JUERGEN DEBUS; FELIX ZWICKER

doi:10.21873/invivo.14305

Article Figures & Data

Figures

Tables

Download figure
Open in new tab
Download powerpoint
Figure 1.
An example of the dose distribution in postmastectomy radiation therapy (PMRT) (ventral thorax wall and the ipsilateral regional/supraclavicular lymph nodes; 50.4 Gy in 28 fractions) of a female patient with left-sided lymph node positive breast cancer after mastectomy using helical tomotherapy is shown in transversal (A), sagittal (B) and coronal (C) section planes. In the computer-tomography slice, the planning target volume (PTV) of the ventral thorax wall and the lymphatic drainage pathway is marked with red outlines. The relative isodoses of the described median PTV dose (50.4 Gy) are shown.
Download figure
Open in new tab
Download powerpoint
Figure 2.
Kaplan-Meier curve for overall survival (OS) in all female patients with breast cancer (n=38) after postmastectomy radiation therapy (PMRT) using helical tomotherapy (hT) (A), or according to grade (G1, G2, G3) (B), tumor stage (T1, T2) (C) and to receptor expression [hormone positive and human epidermal growth factor receptor 2 (HER2)-negative, HER2-positive (3+), triple negative, hormone-positive and HER2-positive] (D). Asterisk (*) indicates significance at p<0.05.
Download figure
Open in new tab
Download powerpoint
Figure 3.
Kaplan-Meier curve for tumor specific survival (TSS) in all female patients with breast cancer (n=38) after postmastectomy radiation therapy (PMRT) using helical tomotherapy (hT) (A), or according to grade (G1, G2, G3) (B), tumor stage (T1/T2, T3/T4) (C) and receptor expression [hormone-positive and human epidermal growth factor receptor 2 (HER2)-negative, HER2-positive, triple negative, hormone-positive and HER2-positive] (D).
Download figure
Open in new tab
Download powerpoint
Figure 4.
Kaplan-Meier curve for local control (LC) in all female patients with breast cancer (n=38) after postmastectomy radiation therapy (PMRT) using helical tomotherapy (hT) (A), or according to grade (G1, G2, G3) (B), tumor stage (T1/T2, T3/T4) (C) and receptor expression [hormone-positive and human epidermal growth factor receptor 2 (HER2)-negative, HER2-positive, triple negative, hormone-positive and HER2-positive] (D).
Download figure
Open in new tab
Download powerpoint
Figure 5.
Kaplan-Meier curve for metastasis free survival (MFS) in all female patients with breast cancer (n=38) after postmastectomy radiation therapy (PMRT) using helical tomotherapy (hT) (A), or according to grade (G1, G2, G3) (B), tumor stage (T1/T2, T3/T4) (C) and receptor expression [hormone-positive and human epidermal growth factor receptor 2 (HER2)-negative, HER2-positive, triple negative, hormone-positive and HER2-positive] (D). *significance at p<0.05.
Download figure
Open in new tab
Download powerpoint
Figure 6.
Kaplan-Meier curve for disease free survival (DFS) in all female patients with breast cancer (n=38) after postmastectomy radiation therapy (PMRT) using helical tomotherapy (hT) (A), or according to grade (G1, G2, G3) (B), tumor stage (T1/T2, T3/T4) (C) and receptor expression [hormone-positive and human epidermal growth factor receptor 2 (HER2)-negative, HER2-positive, triple negative, hormone-positive and HER2-positive] (D). *significance at p<0.05.
Download figure
Open in new tab
Download powerpoint
Figure 7.
Kaplan-Meier curve for secondary malignancy free survival (SMFS) regarding to all female patients with breast cancer (n=38) with local advanced breast cancer after mastectomy and postmastectomy radiation therapy (PMRT) using helical tomotherapy (hT).